Page last updated: 2024-11-05

troglitazone and Cardiomyopathy, Hypertrophic

troglitazone has been researched along with Cardiomyopathy, Hypertrophic in 1 studies

Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.

Cardiomyopathy, Hypertrophic: A form of CARDIAC MUSCLE disease, characterized by left and/or right ventricular hypertrophy (HYPERTROPHY, LEFT VENTRICULAR; HYPERTROPHY, RIGHT VENTRICULAR), frequent asymmetrical involvement of the HEART SEPTUM, and normal or reduced left ventricular volume. Risk factors include HYPERTENSION; AORTIC STENOSIS; and gene MUTATION; (FAMILIAL HYPERTROPHIC CARDIOMYOPATHY).

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Harano, Y1

Reviews

1 review available for troglitazone and Cardiomyopathy, Hypertrophic

ArticleYear
[Lipodystrophia].
    Nihon rinsho. Japanese journal of clinical medicine, 2001, Volume: 59 Suppl 3

    Topics: Animals; Cardiomyopathy, Hypertrophic; Chromans; Diabetes Mellitus; Diagnosis, Differential; Fatty L

2001